- Home
- PRME vs OABI Comparison
PRME vs OABI Comparison
Compare PRME & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- OABI
- Stock Information
- Founded
- PRME 2019
- OABI 2012
- Country
- PRME United States
- OABI United States
- Employees
- PRME N/A
- OABI N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- OABI Health Care
- Exchange
- PRME Nasdaq
- OABI Nasdaq
- Market Cap
- PRME 191.7M
- OABI 198.2M
- IPO Year
- PRME 2022
- OABI N/A
- Fundamental
- Price
- PRME $2.71
- OABI $1.74
- Analyst Decision
- PRME Buy
- OABI Strong Buy
- Analyst Count
- PRME 6
- OABI 3
- Target Price
- PRME $9.38
- OABI $7.00
- AVG Volume (30 Days)
- PRME 3.3M
- OABI 1.1M
- Earning Date
- PRME 08-04-2025
- OABI 08-07-2025
- Dividend Yield
- PRME N/A
- OABI N/A
- EPS Growth
- PRME N/A
- OABI N/A
- EPS
- PRME N/A
- OABI N/A
- Revenue
- PRME $3,846,000.00
- OABI $26,744,000.00
- Revenue This Year
- PRME $104.12
- OABI N/A
- Revenue Next Year
- PRME $196.78
- OABI $45.65
- P/E Ratio
- PRME N/A
- OABI N/A
- Revenue Growth
- PRME 550.76
- OABI 27.07
- 52 Week Low
- PRME $1.11
- OABI $1.22
- 52 Week High
- PRME $6.75
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- PRME 69.76
- OABI 57.18
- Support Level
- PRME $1.56
- OABI $1.55
- Resistance Level
- PRME $2.78
- OABI $1.76
- Average True Range (ATR)
- PRME 0.26
- OABI 0.10
- MACD
- PRME 0.08
- OABI 0.02
- Stochastic Oscillator
- PRME 76.81
- OABI 69.09
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.